Safety and efficacy of intravenous thrombolysis in stroke patients on prior antiplatelet therapy in the WAKE-UP trial.
Benedikt M FreyFlorent BoutitieBastian ChengTae-Hee ChoMartin EbingerMatthias EndresJochen B FiebachJens FiehlerIan FordIvana GalinovicAlina KönigsbergJosep PuigPascal RoyAnke WoutersTim MagnusVincent ThijsRobin LemmensKeith W MuirNorbert NighoghossianSalvador PedrazaClaus Z SimonsenChristian GerloffGötz Thomallanull nullPublished in: Neurological research and practice (2020)
Treatment benefit of intravenous alteplase and rates of post-treatment hemorrhagic transformation were not modified by prior antiplatelet intake among MRI-selected patients with unknown onset stroke. Worse functional outcome in patients on antiplatelets may result from a higher load of cardiovascular co-morbidities in these patients.
Keyphrases
- end stage renal disease
- antiplatelet therapy
- ejection fraction
- newly diagnosed
- prognostic factors
- magnetic resonance imaging
- peritoneal dialysis
- acute coronary syndrome
- clinical trial
- high dose
- percutaneous coronary intervention
- randomized controlled trial
- atrial fibrillation
- study protocol
- acute ischemic stroke
- open label
- subarachnoid hemorrhage
- combination therapy
- phase ii
- replacement therapy